Literature DB >> 15836889

Paraneoplastic stiff-person syndrome: passive transfer to rats by means of IgG antibodies to amphiphysin.

Claudia Sommer1, Andreas Weishaupt, Jörg Brinkhoff, Lydia Biko, Carsten Wessig, Ralf Gold, Klaus V Toyka.   

Abstract

BACKGROUND: Stiff-person syndrome (SPS) with antibodies to amphiphysin is a paraneoplastic disorder of the central nervous system with a putative autoimmune pathogenesis. Proof of a causal role of the antibodies is still lacking for this and all other antibody-associated paraneoplastic syndromes of the central nervous system.
METHODS: We obtained the plasma filtrate of a patient with breast cancer and SPS that responded to therapeutic plasmapheresis. The purified IgG fraction included high-titre antibodies to the synaptic protein amphiphysin. In a cotransfer design, this IgG fraction was injected intraperitoneally into female Lewis rats that had received encephalitogenic T-helper (Th) lymphocytes specific for myelin basic protein, to induce an immune-mediated leaky blood-brain barrier. The rats were followed up with behavioural tests, video photography, and electromyography.
FINDINGS: The injection of the IgG fraction including antibodies to amphiphysin resulted in a dose-dependent stiffness with spasms resembling human SPS. Control IgG injected into rats that had received the same encephalitogenic Th cells had no effect. IgG binding was demonstrated in the central nervous system of rats that showed signs of the disorder.
INTERPRETATION: These experiments support the hypothesis of a pathogenetic role of antibodies to amphiphysin, thus adding paraneoplastic SPS to the group of antibody-mediated autoimmune disorders. RELEVANCE TO PRACTICE: These findings provide a strong argument for a direct pathogenetic role of anti-amphiphysin in this type of SPS and support therapeutic attempts to eliminate these autoantibodies by plasmapheresis. The experimental approach used could help to elucidate the role of autoantibodies in other paraneoplastic syndromes, such as SPS with antibodies to glutamic acid decarboxylase, and others including anti-Hu-associated subacute cerebellar degeneration and limbic encephalitis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15836889     DOI: 10.1016/S0140-6736(05)66376-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  51 in total

1.  Human N-methyl D-aspartate receptor antibodies alter memory and behaviour in mice.

Authors:  Jesús Planagumà; Frank Leypoldt; Francesco Mannara; Javier Gutiérrez-Cuesta; Elena Martín-García; Esther Aguilar; Maarten J Titulaer; Mar Petit-Pedrol; Ankit Jain; Rita Balice-Gordon; Melike Lakadamyali; Francesc Graus; Rafael Maldonado; Josep Dalmau
Journal:  Brain       Date:  2014-11-11       Impact factor: 13.501

Review 2.  Autoimmune stiff person syndrome and related myelopathies: understanding of electrophysiological and immunological processes.

Authors:  Goran Rakocevic; Mary Kay Floeter
Journal:  Muscle Nerve       Date:  2012-05       Impact factor: 3.217

3.  Clinical and immunological diversity of limbic encephalitis: a model for paraneoplastic neurologic disorders.

Authors:  Josep Dalmau; Luis Bataller
Journal:  Hematol Oncol Clin North Am       Date:  2006-12       Impact factor: 3.722

Review 4.  Paraneoplastic syndromes of the CNS.

Authors:  Josep Dalmau; Myrna R Rosenfeld
Journal:  Lancet Neurol       Date:  2008-04       Impact factor: 44.182

Review 5.  Neuropsychological symptoms in paraneoplastic disorders.

Authors:  Raymond Voltz
Journal:  J Neurol       Date:  2007-05       Impact factor: 4.849

6.  Update on paraneoplastic neurologic disorders.

Authors:  Myrna R Rosenfeld; Josep Dalmau
Journal:  Oncologist       Date:  2010-05-17

Review 7.  Neuronal central nervous system syndromes probably mediated by autoantibodies.

Authors:  Aude Chefdeville; Jérôme Honnorat; Christiane S Hampe; Virginie Desestret
Journal:  Eur J Neurosci       Date:  2016-03-28       Impact factor: 3.386

8.  Mild experimental autoimmune encephalitis as a tool to induce blood-brain barrier dysfunction.

Authors:  Michael K Boettger; Andreas Weishaupt; Christian Geis; Klaus V Toyka; Claudia Sommer
Journal:  J Neural Transm (Vienna)       Date:  2009-11-28       Impact factor: 3.575

Review 9.  [Rituximab in treatment for neuroimmunological diseases].

Authors:  A Schröder; G Ellrichmann; G Chehab; M Schneider; R A Linker; R Gold
Journal:  Nervenarzt       Date:  2009-02       Impact factor: 1.214

10.  A new Purkinje cell antibody (anti-Ca) associated with subacute cerebellar ataxia: immunological characterization.

Authors:  Sven Jarius; Klaus P Wandinger; Sigrun Horn; Heike Heuer; Brigitte Wildemann
Journal:  J Neuroinflammation       Date:  2010-03-12       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.